Literature DB >> 11295634

The Prostate Cancer Prevention Trial: Current status and lessons learned.

I M Thompson1, M Kouril, E A Klein, C A Coltman, A Ryan, P Goodman.   

Abstract

The Prostate Cancer Prevention Trial is the first phase 3 prevention trial for prostate cancer in the United States. The implementation of a large, randomized trial has provided a wealth of information that will aid in future cancer chemopreventive studies in US men. The experience from the implementation of the Prostate Cancer Prevention Trial was reviewed. Lessons learned from the study include: (1) US men are willing to enroll in prevention trials; (2) participants in chemoprevention trials are well educated and healthy; (3) the successful cancer prevention trial is viewed by participants as a "men's health trial"; (4) data management and discipline coordination at participating institutions are critical; (5) study design change is commonly required owing to changes in clinical practice over the course of the trial; and (6) training of institutional staff is essential. With proper design, robust data management, and a flexible staff, large-scale randomized chemoprevention trials can be accomplished in the United States. With the extraordinary number of potential agents, it is expected that much will be accomplished with this strategy in the near future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295634     DOI: 10.1016/s0090-4295(00)00980-8

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

Review 1.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial.

Authors:  Sarah H Nash; Jeannette M Schenk; Alan R Kristal; Phillis J Goodman; M Scott Lucia; Howard L Parnes; Ian M Thompson; Scott M Lippman; Xiaoling Song; Bora Gurel; Angelo De Marzo; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-29

3.  Chemopreventive trials in urologic cancer.

Authors:  Vahagn R Ashughyan; Sibylle Marihart; Bob Djavan
Journal:  Rev Urol       Date:  2006

4.  An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth.

Authors:  Zhang Weihua; Richard Lathe; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

Review 5.  Systematic review of electronically delivered behavioral obesity prevention interventions targeting men.

Authors:  Adam P Knowlden; Amanda H Wilkerson; Kandyce B Dunlap; Michael Stellefson; Odunayo A Elijah
Journal:  Obes Rev       Date:  2022-04-18       Impact factor: 10.867

Review 6.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 7.  What's new in the field of prostate cancer chemoprevention?

Authors:  Kanwaljit Mahal; Javier Hernandez; Joseph W Basler; Ian M Thompson
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

8.  Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.

Authors:  Sarah H Nash; Cathee Till; Xiaoling Song; M Scott Lucia; Howard L Parnes; Ian M Thompson; Scott M Lippman; Elizabeth A Platz; Jeannette Schenk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-12       Impact factor: 4.254

Review 9.  What's new in the field of prostate cancer chemoprevention?

Authors:  Kanwaljit Mahal; Javier Hernandez; Joseph W Basler; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.